Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
US FDA to reconsider decision barring compounded versions of Lilly weight loss drug
The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.
In stark reversal, FDA to reconsider removal of Eli Lilly weight loss drug from shortage list
The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, from its shortage list.
Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves
Eli Lilly And Co. (NYSE:LLY) is ramping up its legal campaign against the compounding companies temporarily allowed to make and sell copycat versions of its blockbuster drugs for weight loss until a U.
Knockoff weight loss drug sellers are fighting back against Eli Lilly and the FDA
Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss drugs during widespread shortages to halt production now that supplies are stabilizing.
As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
Compounding Group Sues FDA for Removing Lilly's Weight Loss Drug From Shortage List
A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s blockbuster weight loss and diabetes drugs from its shortage list last week,
Lilly Weight-Loss Drug Copycat Makers Sue FDA Over Shortage End
A group representing companies that made copycat versions of Eli Lilly & Co.’s weight-loss drugs sued the US Food and Drug Administration over the agency’s decision to remove Lilly’s medications from its shortage list.
Eli Lilly obesity drug shortage ends fueling lawsuit against FDA
An industry group representing companies that manufactured the copycat versions of Eli Lilly's (NYSE:LLY) highly popular weight loss therapy tirzepatide sued the U.S. FDA on Monday over the agency's decision to declare an end to the drug's shortage last week.
With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
The popularity of GLP-1 weight loss drugs has soared, which had created a shortage among many of the drugs, including Eli Lilly's (NYSE: LLY) popular Mounjaro and Zepbound. However, the U.S. Food and Drug Administration (FDA) recently removed both drugs from its shortage list,
Compounding group sues FDA for removing Lilly’s obesity drug from its shortages list
A trade group representing compounding pharmacies sued the FDA for a “reckless and arbitrary” decision to remove Eli Lilly's tirzepatide from an official shortages list.
Trade group sues FDA for removing Lilly weight-loss drug from shortage list
A group representing companies that produce copycat versions of Eli Lilly weight loss medications has filed a lawsuit against the FDA following the agency's recent decision to remove the drug's from its shortage list,
Hoodline
6h
Michigan Attorney General Fights to Revoke Decades-Old Rulings Shielding Pharma Giant Eli Lilly from Insulin Pricing Scrutiny
Michigan's Supreme Court reexamines rulings that may affect how the state's consumer protection laws apply to insulin pricing ...
1d
on MSN
Eli Lilly widens obesity reach with $1.4B KeyBioscience deal
Eli Lilly (NYSE:LLY) has expanded its ongoing collaboration with Swiss biotech KeyBioscience in a bid to obtain global rights ...
14h
Eli Lilly & Co: Buy Rating Justified Despite Short-Term Sales Miss
Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target ...
1d
AG, Eli Lilly spar before the Michigan Supreme Court over insulin pricing investigation
The justices are considering an effort challenging longstanding case law blocking the state’s ability to probe inflated drug ...
8h
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.
1d
Novo Nordisk, Eli Lilly and the GLP-1 economy
Eli Lilly’s shares have surged 750 per cent over five years. Novo Nordisk’s are up about 360 per cent in the same period.
FierceBiotech
2d
Eli Lilly delivers for AI-powered insitro to clear siRNA molecules’ path to clinic
Insitro has teamed up with Eli Lilly to help power programs into the clinic, tapping the Big Pharma for an option on ...
FiercePharma
11h
Lilly's manufacturing splurge continues with $200M expansion in China
Lilly has earmarked $200 million for the upgrade, a company spokesperson confirmed to Fierce Pharma. The new project will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
AI
Food and Drug Administration
Artificial intelligence
Zepbound
Novo Nordisk
Feedback